CBD, Food & Drink, HT Premium, Legal, Legislation, News, North America, Regulatory, USA

Good for Epidiolex, but rescheduling overreaches on CBD

U.S. Dept. of Justice, DEA
Share this:
  • 101

A rescheduling that makes CBD-based drug Epidiolex legal has been applauded as a win for cannabinoid-based therapies, but critics say the ruling is another case of the U.S. Drug Enforcement Administration (DEA) overstepping its bounds.

You need to login to view the rest of the content. Please . Not a Member? Join Us

Get Hemp Industry Updates

* indicates required

Do you want event updates?